Aclarion (ACON) Competitors $7.40 -0.08 (-1.12%) Closing price 10/3/2025 03:50 PM EasternExtended Trading$7.50 +0.11 (+1.47%) As of 10/3/2025 06:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock ACON vs. BRTX, BGLC, KDLY, NIVF, DHAC, BACK, OTRK, BTTX, UPHL, and OPGNShould you be buying Aclarion stock or one of its competitors? The main competitors of Aclarion include Biorestorative Therapies (BRTX), BioNexus Gene Lab (BGLC), Kindly MD (KDLY), NewGenIvf Group (NIVF), Digital Health Acquisition (DHAC), IMAC (BACK), Ontrak (OTRK), Better Therapeutics (BTTX), UpHealth (UPHL), and OpGen (OPGN). These companies are all part of the "healthcare" industry. Aclarion vs. Its Competitors Biorestorative Therapies BioNexus Gene Lab Kindly MD NewGenIvf Group Digital Health Acquisition IMAC Ontrak Better Therapeutics UpHealth OpGen Aclarion (NASDAQ:ACON) and Biorestorative Therapies (NASDAQ:BRTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, analyst recommendations, media sentiment and institutional ownership. Is ACON or BRTX more profitable? Biorestorative Therapies has a net margin of -1,772.40% compared to Aclarion's net margin of -11,238.59%. Aclarion's return on equity of -83.63% beat Biorestorative Therapies' return on equity.Company Net Margins Return on Equity Return on Assets Aclarion-11,238.59% -83.63% -76.55% Biorestorative Therapies -1,772.40%-137.00%-88.31% Does the media refer more to ACON or BRTX? In the previous week, Aclarion had 4 more articles in the media than Biorestorative Therapies. MarketBeat recorded 4 mentions for Aclarion and 0 mentions for Biorestorative Therapies. Aclarion's average media sentiment score of 0.67 beat Biorestorative Therapies' score of 0.00 indicating that Aclarion is being referred to more favorably in the media. Company Overall Sentiment Aclarion Positive Biorestorative Therapies Neutral Do analysts recommend ACON or BRTX? Aclarion currently has a consensus target price of $11,758.50, suggesting a potential upside of 158,884.59%. Given Aclarion's stronger consensus rating and higher possible upside, equities research analysts plainly believe Aclarion is more favorable than Biorestorative Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aclarion 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50Biorestorative Therapies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Which has higher earnings & valuation, ACON or BRTX? Aclarion has higher earnings, but lower revenue than Biorestorative Therapies. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAclarion$50K85.79-$6.99MN/AN/ABiorestorative Therapies$400K29.93-$8.98M-$1.27-1.18 Do insiders and institutionals hold more shares of ACON or BRTX? 7.5% of Aclarion shares are held by institutional investors. Comparatively, 69.4% of Biorestorative Therapies shares are held by institutional investors. 0.8% of Aclarion shares are held by insiders. Comparatively, 30.8% of Biorestorative Therapies shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has more risk and volatility, ACON or BRTX? Aclarion has a beta of 1.4, suggesting that its share price is 40% more volatile than the S&P 500. Comparatively, Biorestorative Therapies has a beta of -0.69, suggesting that its share price is 169% less volatile than the S&P 500. SummaryAclarion beats Biorestorative Therapies on 9 of the 13 factors compared between the two stocks. Get Aclarion News Delivered to You Automatically Sign up to receive the latest news and ratings for ACON and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ACON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACON vs. The Competition Export to ExcelMetricAclarionMedical Services IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.28M$8.23B$6.13B$10.58BDividend YieldN/A2.80%5.65%4.69%P/E RatioN/A75.2686.9626.71Price / Sales85.7940.93605.32131.77Price / CashN/A23.0137.9061.31Price / Book0.146.7612.556.55Net Income-$6.99M$250.93M$3.31B$277.50M7 Day Performance-2.94%2.29%4.28%2.42%1 Month Performance3.64%3.27%6.90%8.63%1 Year Performance-99.52%10.51%70.54%31.60% Aclarion Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACONAclarion2.052 of 5 stars$7.40-1.1%$11,758.50+158,884.6%-99.5%$4.28M$50K0.007BRTXBiorestorative Therapies1.4279 of 5 stars$1.45+1.4%N/A-6.8%$11.41M$400K-1.147BGLCBioNexus Gene Lab0.0573 of 5 stars$5.47-3.2%N/A+25.4%$10.15M$9.51M0.0030News CoveragePositive NewsShort Interest ↑KDLYKindly MDN/A$1.15-8.7%N/A+9.4%$6.93M$2.47M-1.49N/AHigh Trading VolumeNIVFNewGenIvf GroupN/A$1.81-1.6%N/A-99.7%$3.96M$5.43M0.00N/APositive NewsGap DownDHACDigital Health AcquisitionN/A$0.64-0.8%N/A-50.2%$2.29MN/A0.002,021High Trading VolumeBACKIMACN/A$0.07-12.2%N/A-93.6%$170K$72.05K0.00180News CoverageGap DownOTRKOntrak2.7902 of 5 stars$0.02-24.9%$3.00+13,536.4%-98.9%$93K$10.18M0.00250Positive NewsGap DownBTTXBetter TherapeuticsN/A$0.00flatN/AN/A$5KN/A0.0040UPHLUpHealthN/A$0.00flatN/A-99.7%$4K$130M0.001,750OPGNOpGenN/A$0.00flatN/AN/A$1K$2.67M0.00100High Trading Volume Related Companies and Tools Related Companies Biorestorative Therapies Competitors BioNexus Gene Lab Competitors Kindly MD Competitors NewGenIvf Group Competitors Digital Health Acquisition Competitors IMAC Competitors Ontrak Competitors Better Therapeutics Competitors UpHealth Competitors OpGen Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACON) was last updated on 10/5/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aclarion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aclarion With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
